Regeneron Pharmaceuticals, Inc.Tarrytown, United States
Disclosure information not submitted.
SUN-397 - In-Vitro Properties of REGN24493, A Novel TSHR Blocking Mab for the Treatment of Graves' Disease and Thyroid Eye Disease
Sunday, June 14, 20269:00 AM - 4:00 PM CT